Damora Therapeutics, Inc. (DMRA): Entry into a Material Definitive Agreement
Damora Therapeutics, Inc. (DMRA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-3.1 3 dmra-ex3_1.htm EX-3.1 EX-3.1 Exhibit 3.1 THE COMPANIES ACT (AS AMENDED) COMPANY LIMITED BY SHARES Memorandum OF association of Damora Therapeutics, Inc. (ADOPTED BY SPECIAL RESOLUTION PASSED ON 9 FEBRUARY 2026 AND EFFECTIVE AS OF 16 JULY 2026) THE COMPANIES ACT (AS AMEND
How this was made
The 30-second read
Why it matters
Without the agreement’s substantive details, the only actionable takeaway is that management asserts the agreement is material, which increases the need for rapid document review.
Market read
Material definitive agreement disclosure can move micro/small-cap biotech names, but the excerpt does not provide the information needed to judge magnitude or direction.
What to watch
Traders should verify the full Item 1.01 exhibit and any referenced agreements for counterparty, cash consideration, milestones, termination rights, and any change-of-control or financing covenants.
Background
This is an SEC Form 8-K (Item 1.01) for Damora Therapeutics, with the excerpt showing memorandum/articles language rather than the agreement’s commercial terms.
Ticker impact
Damora Therapeutics filed an 8-K stating it entered a material definitive agreement, but the provided exhibit text is mostly organizational boilerplate.
Limited immediate directional conviction until the agreement’s substantive terms are available.
An 8-K Item 1.01 is potentially market-moving, but the supplied content does not include the agreement details needed to assess risk or upside.
Market effects
No clear sector read-through because the agreement terms are not disclosed in the provided text.
None identifiable from the excerpt.
None identifiable from the excerpt.
Counterpoint
The agreement could be routine (e.g., governance or administrative) and may not warrant repricing if terms are non-economic.
Key entities
- issuerDamora Therapeutics, Inc.
Subject of the 8-K, filed for entry into a material definitive agreement.
